BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 28634282)

  • 1. Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of
    Ibrahimpasic T; Xu B; Landa I; Dogan S; Middha S; Seshan V; Deraje S; Carlson DL; Migliacci J; Knauf JA; Untch B; Berger MF; Morris L; Tuttle RM; Chan T; Fagin JA; Ghossein R; Ganly I
    Clin Cancer Res; 2017 Oct; 23(19):5970-5980. PubMed ID: 28634282
    [No Abstract]   [Full Text] [Related]  

  • 2. The frequency of mutations in advanced thyroid cancer in Japan: a single-center study.
    Toda S; Iwasaki H; Okubo Y; Hayashi H; Kadoya M; Takahashi H; Yokose T; Hiroshima Y; Masudo K
    Endocr J; 2024 Jan; 71(1):31-37. PubMed ID: 38044137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spectrum of TERT promoter mutations and mechanisms of activation in thyroid cancer.
    Panebianco F; Nikitski AV; Nikiforova MN; Nikiforov YE
    Cancer Med; 2019 Oct; 8(13):5831-5839. PubMed ID: 31408918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Additional Oncogenic Alterations in RAS-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes.
    Bikas A; Ahmadi S; Pappa T; Marqusee E; Wong K; Nehs MA; Cho NL; Haase J; Doherty GM; Sehgal K; Barletta JA; Alexander EK; Landa I
    Clin Cancer Res; 2023 Jul; 29(14):2678-2685. PubMed ID: 37260297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The genomic and evolutionary landscapes of anaplastic thyroid carcinoma.
    Zeng PYF; Prokopec SD; Lai SY; Pinto N; Chan-Seng-Yue MA; Clifton-Bligh R; Williams MD; Howlett CJ; Plantinga P; Cecchini MJ; Lam AK; Siddiqui I; Wang J; Sun RX; Watson JD; Korah R; Carling T; Agrawal N; Cipriani N; Ball D; Nelkin B; Rooper LM; Bishop JA; Garnis C; Berean K; Nicolson NG; Weinberger P; Henderson YC; Lalansingh CM; Tian M; Yamaguchi TN; Livingstone J; Salcedo A; Patel K; Vizeacoumar F; Datti A; Xi L; Nikiforov YE; Smallridge R; Copland JA; Marlow LA; Hyrcza MD; Delbridge L; Sidhu S; Sywak M; Robinson B; Fung K; Ghasemi F; Kwan K; MacNeil SD; Mendez A; Palma DA; Khan MI; Shaikh M; Ruicci KM; Wehrli B; Winquist E; Yoo J; Mymryk JS; Rocco JW; Wheeler D; Scherer S; Giordano TJ; Barrett JW; Faquin WC; Gill AJ; Clayman G; Boutros PC; Nichols AC
    Cell Rep; 2024 Mar; 43(3):113826. PubMed ID: 38412093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive genomic profiling from C-CAT database unveiled over 80% presence of oncogenic drivers in anaplastic thyroid carcinoma including BRAF, RAS family, NF1, and FGFR1.
    Saito Y; Kage H; Kobayashi K; Kamogashira T; Fukuoka O; Yamamura K; Yamashita S; Tanabe M; Oda K; Kondo K
    Clin Endocrinol (Oxf); 2024 Jun; ():. PubMed ID: 38853441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A genome-wide association study yields five novel thyroid cancer risk loci.
    Gudmundsson J; Thorleifsson G; Sigurdsson JK; Stefansdottir L; Jonasson JG; Gudjonsson SA; Gudbjartsson DF; Masson G; Johannsdottir H; Halldorsson GH; Stacey SN; Helgason H; Sulem P; Senter L; He H; Liyanarachchi S; Ringel MD; Aguillo E; Panadero A; Prats E; Garcia-Castaño A; De Juan A; Rivera F; Xu L; Kiemeney LA; Eyjolfsson GI; Sigurdardottir O; Olafsson I; Kristvinsson H; Netea-Maier RT; Jonsson T; Mayordomo JI; Plantinga TS; Hjartarson H; Hrafnkelsson J; Sturgis EM; Thorsteinsdottir U; Rafnar T; de la Chapelle A; Stefansson K
    Nat Commun; 2017 Feb; 8():14517. PubMed ID: 28195142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic landscape and clinical features of advanced thyroid carcinoma: a national database study in Japan.
    Toda S; Hiroshima Y; Iwasaki H; Masudo K
    J Clin Endocrinol Metab; 2024 Apr; ():. PubMed ID: 38630010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer.
    da Silva EM; Selenica P; Vahdatinia M; Pareja F; Da Cruz Paula A; Ferrando L; Gazzo AM; Dopeso H; Ross DS; Bakhteri A; Riaz N; Chandarlapaty S; Razavi P; Norton L; Wen HY; Brogi E; Weigelt B; Zhang H; Reis-Filho JS
    NPJ Breast Cancer; 2021 Apr; 7(1):43. PubMed ID: 33863915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomically driven precision medicine to improve outcomes in anaplastic thyroid cancer.
    Pinto N; Black M; Patel K; Yoo J; Mymryk JS; Barrett JW; Nichols AC
    J Oncol; 2014; 2014():936285. PubMed ID: 25276134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogene-induced senescence and its evasion in a mouse model of thyroid neoplasia.
    Bellelli R; Vitagliano D; Federico G; Marotta P; Tamburrino A; Salerno P; Paciello O; Papparella S; Knauf JA; Fagin JA; Refetoff S; Troncone G; Santoro M
    Mol Cell Endocrinol; 2018 Jan; 460():24-35. PubMed ID: 28652169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the Seventh and Eighth Editions of the American Joint Committee on Cancer/Union for International Cancer Control Tumor-Node-Metastasis Staging System for Differentiated Thyroid Cancer.
    Kim M; Kim WG; Oh HS; Park S; Kwon H; Song DE; Kim TY; Shong YK; Kim WB; Sung TY; Jeon MJ
    Thyroid; 2017 Sep; 27(9):1149-1155. PubMed ID: 28635571
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Bastos AU; de Jesus AC; Cerutti JM
    Eur J Endocrinol; 2018 Jan; 178(1):83-91. PubMed ID: 29046324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers.
    Pozdeyev N; Gay LM; Sokol ES; Hartmaier R; Deaver KE; Davis S; French JD; Borre PV; LaBarbera DV; Tan AC; Schweppe RE; Fishbein L; Ross JS; Haugen BR; Bowles DW
    Clin Cancer Res; 2018 Jul; 24(13):3059-3068. PubMed ID: 29615459
    [No Abstract]   [Full Text] [Related]  

  • 15. Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer.
    Liu R; Zhang T; Zhu G; Xing M
    Nat Commun; 2018 Feb; 9(1):579. PubMed ID: 29422527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.
    Sherman EJ; Dunn LA; Ho AL; Baxi SS; Ghossein RA; Fury MG; Haque S; Sima CS; Cullen G; Fagin JA; Pfister DG
    Cancer; 2017 Nov; 123(21):4114-4121. PubMed ID: 28662274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Insights in Thyroid Cancer and p53 Family Proteins.
    Manzella L; Stella S; Pennisi MS; Tirrò E; Massimino M; Romano C; Puma A; Tavarelli M; Vigneri P
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28635633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies.
    Molinaro E; Romei C; Biagini A; Sabini E; Agate L; Mazzeo S; Materazzi G; Sellari-Franceschini S; Ribechini A; Torregrossa L; Basolo F; Vitti P; Elisei R
    Nat Rev Endocrinol; 2017 Nov; 13(11):644-660. PubMed ID: 28707679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RBM10 promotes transformation-associated processes in small cell lung cancer and is directly regulated by RBM5.
    Loiselle JJ; Roy JG; Sutherland LC
    PLoS One; 2017; 12(6):e0180258. PubMed ID: 28662214
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.